Clinical Trial Update: A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial compares SB27, a pembrolizumab biosimilar, with Keytruda (pembrolizumab) in patients with metastatic non-squamous non-small cell lung cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• SB27 (pembrolizumab biosimilar)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Non-small Cell Lung Cancer Stage IV | Phase 3 | Status: ACTIVE_NOT_RECRUITING